Health News Releases

  • Today October 6
October 04, 16:50
Ferring Pharmaceuticals bolsters global gene therapy supply chain with European manufacturing facility
Ferring Pharmaceuticals today announced the opening of a state-of-the-art global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin® (nado
October 02, 13:45
Crown Bioscience Expands Singapore Facility with Advanced Oncology Models and Imaging Capabilities
Crown Bioscience (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.crownbio.com%2F&esheet=54128719&newsitemid=20241001076209&lan=en-US&anchor=Crown+Bioscience&index=1&md5=d0a4aa1a
AOP Health CEO Martin Steinhart (Copyright: AOP Health/Studio Koekart)
October 02, 13:45
Cancer Therapy: AOP Health Investigates a New Approach Targeting Cancer Stem Cells
AOP Orphan Pharmaceuticals GmbH (AOP Health) in collaboration with Leukos Biotech has achieved a key milestone. The first patient was included in the phase I clinical trial SERONCO-1, in which a subst
October 02, 09:42
Ferring Demonstrates Effectiveness of a Treat-to-Target Approach in Mild-to-Moderate Ulcerative Colitis in First Major Study
Ferring Pharmaceuticals today announces results from the OPTIMISE study showing the first real-world evidence of the effectiveness of a treat-to-target (T2T) approach based on faecal calprotectin (FC)
Novotech is a Great Place to Work Certified in the USA (Graphic: Business Wire)
October 01, 15:25
Novotech Earns Great Place to Work® Certification in the United States
Novotech, a global full-service clinical Contract Research Organization (CRO), is proud to announce that it has been certified as a Great Place to Work® in the United States. This award reflects Novot
October 01, 11:20
SK pharmteco Invests $260 Million to Expand Global Small Molecule and Peptide Production
SK pharmteco, a global contract development and manufacturing organization (CDMO), today announced a major expansion of its small molecule and peptide production capabilities with a $260 million inves
September 27, 14:19
Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors
BeiGene (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.beigene.com%2F&esheet=54127370&newsitemid=20240926501587&lan=en-US&anchor=BeiGene&index=1&md5=35ef0ca3f29c557d3fdea29b228
Logo
September 26, 16:40
Merz Aesthetics Announces the Launch of Ultherapy PRIME Platform as the Next Generation of Nonsurgical Skin Lifting Treatments
Merz Aesthetics, the world’s largest dedicated medical aesthetics business, announced today the launch of Ultherapy PRIME - a noninvasive, FDA-cleared medical aesthetics treatment that provides a trul
PCI Pharma Services is investing more than $365 million in infrastructure supporting the clinical an
September 26, 14:25
PCI Pharma Services Invests Over $365 Million in EU, US Facilities for Clinical and Commercial Supply of Advanced Drug Delivery and Drug-Device Combination Products
PCI Pharma Services, (“PCI”) a leading global contract development and manufacturing organization (CDMO) focused on biopharma’s most complex therapies, is investing more than $365 million in infrastru
September 26, 11:15
Medidata Extends Its Commitment to the Patient Experience with the Launch of Patient Payments
Medidata (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.medidata.com&esheet=54126085&newsitemid=20240925388965&lan=en-US&anchor=Medidata&index=1&md5=2a7f1d88d61b0fe6c85a6c34c7cb
September 26, 10:50
Fujirebio Submits FDA Regulatory Filing for Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease
Fujirebio today announced that its wholly-owned subsidiary Fujirebio Diagnostics, Inc. has filed its Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test with the U.S. Food
September 25, 15:25
Rigaku Holdings Corporation: Approval of Listing on the Tokyo Stock Exchange Prime Market
Rigaku Holdings Corporation, a global solution partner for X-ray analysis (headquarters: Akishima, Tokyo; president and CEO: Jun Kawakami; “Rigaku”), has been approved for a new listing of its shares
September 25, 14:37
EADV 2024 Late Breaking News Sessions: New Galderma Data Demonstrating Nemolizumab’s Long-term Efficacy and Safety in Atopic Dermatitis and Durability in Prurigo Nodularis to Be Shared During Three Oral Presentations
Galderma today announced that it will present new data from the ARCADIA and OLYMPIA clinical trial programs investigating nemolizumab in atopic dermatitis and prurigo nodularis, respectively, at the 2
September 25, 14:10
Aurion Biotech Launches Vyznova® (neltependocel) in Japan for the Treatment of Bullous Keratopathy of the Cornea
Aurion Biotech (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.aurionbiotech.com%2F&esheet=54125897&newsitemid=20240924085009&lan=en-US&anchor=Aurion+Biotech&index=1&md5=0d280e30
September 25, 09:03
Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=54124287&newsitemid=20240918509211&lan=en-US&anchor=TSE%3A4502%2FNYSE%
September 24, 14:50
Zambon Taps Kinaxis to Enhance Transparency Across Global Supply Chain
Kinaxis® Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.kinaxis.com%2Fen&esheet=54125291&newsitemid=20240923380059&lan=en-US&anchor=Kinaxis%26%23174%3B+Inc.&index=1&md5=23
September 24, 14:40
Kenvue Drives Climate Action Strategy Forward
Kenvue Inc. (NYSE: KVUE) (“Kenvue” or the “Company”), the maker of iconic brands such as Aveeno®, Listerine®, Neutrogena® and Tylenol®, is advancing progress toward the climate change goals outlined i
The parable of the lost sheep mirrors our journey to find a solution for Duchenne Muscular Dystrophy
September 24, 14:00
Neu-REFIX Beta glucan receives rare pediatric disease and orphan drug designations from the US FDA for treatment of Duchenne Muscular Dystrophy
Neu REFIX Beta glucan, made in Japan has received both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (US FDA) for treatment of
September 24, 09:03
Debiopharm Recognizes Groundbreaking Japanese Cancer Research During the 83rd Annual Meeting of the Japanese Cancer Association
Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced the recognitio
David M. Brogan, MD, MSc, Assistant Professor, Orthopaedic Surgery, Division of Hand and Microsurger
September 20, 17:00
Neuraptive Therapeutics Announces Presentation of Phase 2 Topline Interim Results for NTX-001 at the 2024 American Society for Surgery of the Hand (ASSH) Annual Meeting
Neuraptive Therapeutics Inc., a leading biopharmaceutical company focused on novel treatments for peripheral nerve injuries, today announced that interim topline results from its ongoing Phase 2 NEURO
September 20, 14:20
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, and Dermavant Sciences Ltd. announced today that they have entered into a definit
September 20, 09:49
Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=54124174&newsitemid=20240919392083&lan=en-US&anchor=TSE%3A4502%2FNYSE%
September 20, 09:45
Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries
Takeda (TOKYO:4502/NYSE: TAK) today committed JPY4.6 billion (Approx. USD 32 million) to five new Global Corporate Social Responsibility (CSR) partners as part of the company’s ongoing commitment to i
September 19, 14:35
Medidata Recognized as a Leader in Everest Group’s Inaugural Electronic Data Capture PEAK Matrix® Assessment
Medidata, a Dassault Systèmes brand and the leading provider of clinical trial solutions to the life sciences industry, has been recognized as a Leader in Everest Group's first-ever PEAK Matrix® Asses
September 18, 15:15
Viromed Medical AG Plans to Acquire All Shares of ActivCell Group AG by Way of a Capital Increase Against Contribution in Kind with Exclusion of Subscription Rights
Viromed Medical AG (Ticker: VMED (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Feqs-cockpit.com%2Fcgi-bin%2Ffncls.ssp%3Ffn%3Dredirect%26url%3D03003d462bf07ae5fbd5a9dd7d755919%26app
25 per page50 per page75 per page100 per page